Möchten Sie immer auf dem neuesten Stand bleiben?

Dublin, Sept. 16, 2025 (GLOBE NEWSWIRE) -- The "Europe Refractory Epilepsy Treatment Market: Analysis and Forecast, 2025-2035" report has been added to ResearchAndMarkets.com's offering.The Europe...

Dublin, Sept. 16, 2025 (GLOBE NEWSWIRE) -- The "Asia-Pacific Refractory Epilepsy Treatment Market: Analysis and Forecast, 2025-2035" report has been added to ResearchAndMarkets.com's offering.The...

BILTHOVEN, Netherlands and BOSTON, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Avania, the leading global MedTech advisory and clinical development partner, is pleased to announce strategic leadership...

PannTheraPi se prépare pour mener son premier essai clinique de phase IIa avec le PTI5803 chez des patients atteints d'épilepsie résistante et accélérer le développement de son portefeuille...

PannTheraPi prepares plans to conduct its first Phase IIa clinical trial with PTI5803 in patients with resistant epilepsy and accelerate the development of its proprietary pipeline Pre-submission...

Brain Injury Association of America honors Centre for Neuro Skills' Dr. Mark Ashley as 2025 Luminary of the Year for contributions in brain injury field

Highlights Granted U.S. FDA Fast Track Designation for ATH434 to treat Multiple System Atrophy (MSA)Reported positive topline data from open-label Phase 2 clinical trial of ATH434 in MSAPresented...

FREIBURG, Germany, July 29, 2025 (GLOBE NEWSWIRE) -- CorTec GmbH, a pioneer in active implantable medical technologies, today announced the first human implantation of its proprietary BCI system,...

– Peer-reviewed publication in Annals of Clinical and Translational Neurology highlights the use of the MSA Atrophy Index developed to diagnose and track disease progression in Multiple System Atrophy...

PRESS RELEASE AB SCIENCE HAS RECEIVED APPROVAL FROM SEVERAL EUROPEAN COUNTRIES TO INITIATE THE CONFIRMATORY PHASE 3 STUDY OF MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS THIS APPROVAL FOLLOWS PROTOCOL...